This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Sep 20;8(11):610.

doi: 10.1038/nrcardio.2011.145.

Acute coronary syndromes: Lackluster RUBY is received with some disappointment

Bryony M Mearns

PMID: 21931363
DOI: 10.1038/nrcardio.2011.145

Comment

Acute coronary syndromes: Lackluster RUBY is received with some disappointment

Bryony M Mearns. Nat Rev Cardiol. 2011.

. 2011 Sep 20;8(11):610.

doi: 10.1038/nrcardio.2011.145.

Author

Bryony M Mearns

PMID: 21931363
DOI: 10.1038/nrcardio.2011.145

No abstract available

PubMed Disclaimer

Comment on

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. Steg PG, et al. Eur Heart J. 2011 Oct;32(20):2541-54. doi: 10.1093/eurheartj/ehr334. Epub 2011 Aug 30. Eur Heart J. 2011. PMID: 21878434 Free PMC article. Clinical Trial.

References

1. Eur Heart J. 2011 Oct;32(20):2541-54 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.